Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameProfessor Sharon Glynn

Lambe Institute for Translational Research

University of Galway

Webpage:nuigalway.ie

Email hidden; Javascript is required.

Research Fields
  • genetics, genomics and molecular biology
  • cancer/oncology
  • epidemiology/population health research
Postgrad Medical Specialties
  • Medicine
  • Surgery
  • Pathology
  • Public Health
Medical Subspecialties
  • Immunology
  • Oncology
  • Pharmacology
My Work

The Glynn lab focuses on understanding inflammation related mechanisms and how they contribute to the initiation and progression of breast and prostate cancer contributing to poor patient outcomes. The lab has three main focuses of interest.
1. Nitrosative stress due to inducible nitric oxide synthase overexpression and its consequences for poor outcome in triple negative breast cancer.
2. The role of human endogenous retrovirus K in breast and prostate tumour progression.
3. Role of tumour infiltrating lymphocytes in triple negative breast cancer progression

Recent Publications Include:
Walsh EM, Shalaby A, O'Loughlin M, Keane N, Webber MJ, Kerin MJ, Keane MM, Glynn SA, Callagy GM. Outcome for triple negative breast cancer in a
retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. Breast Cancer Res Treat. 2019 Feb;174(1):1-13.

O'Loughlin M, Andreu X, Bianchi S, Chemielik E, Cordoba A, Cserni G, Figueiredo P, Floris G, Foschini MP, Heikkilä P, Kulka J, Liepniece-Karele I,
Regitnig P, Reiner A, Ryska A, Sapino A, Shalaby A, Stovgaard ES, Quinn C, Walsh EM, Zolota V, Glynn SA, Callagy G. Reproducibility and predictive value of
scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Res Treat. 2018 Aug;171(1):1-9.

Ridge SM, Bhattacharyya D, Dervan E, Naicker SD, Burke AJ, Murphy JM, O'leary K, Greene J, Ryan AE, Sullivan FJ, Glynn SA. Secreted factors from metastatic
prostate cancer cells stimulate mesenchymal stem cell transition to a pro-tumourigenic 'activated' state that enhances prostate cancer cell migration. Int J Cancer. 2018 May 15;142(10):2056-2067.

Basudhar D*, Glynn SA*, Greer M, Somasundaram V, No JH, Scheiblin DA, Garrido P, Heinz WF, Ryan AE, Weiss JM, Cheng RYS, Ridnour LA, Lockett SJ, McVicar DW, Ambs S, Wink DA. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13030-13035. *Joint first

Garrido P, Shalaby A, Walsh EM, Keane N, Webber M, Keane MM, Sullivan FJ, Kerin MJ, Callagy G, Ryan AE, Glynn SA. Impact of inducible nitric oxide synthase
(iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget. 2017 Jul 26;8(46):80568-80588.

Prueitt RL*, Wallace TA*, Glynn SA*, Yi M, Tang W, Luo J, Dorsey TH, Stagliano KE, Gillespie JW, Hudson RS, Terunuma A, Shoe JL, Haines DC, Yfantis HG, Han M,
Martin DN, Jordan SV, Borin JF, Naslund MJ, Alexander RB, Stephens RM, Loffredo CA, Lee DH, Putluri N, Sreekumar A, Hurwitz AA, Ambs S. An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. Cancer Res. 2016 Mar 1;76(5):1055-1065. *Joint first

Wallace TA, Downey RF, Seufert CJ, Schetter A, Dorsey TH, Johnson CA, Goldman R, Loffredo CA, Yan P, Sullivan FJ, Giles FJ, Wang-Johanning F, Ambs S, Glynn SA.
Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis. 2014
Sep;35(9):2074-83.

Toner AP, McLaughlin F, Giles FJ, Sullivan FJ, O'Connell E, Carleton LA, Breen L, Dunne G, Gorman AM, Lewis JD, Glynn SA. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Br J Cancer. 2013 Oct 15;109(8):2131-41.

Scroll to Top